GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes

Hormone and Metabolic Research

Volumn 36, Issue 11-12, 2004, Pages 867-876

  Ahren B ^a   Schmitz, O ^b,c  

^a LUND UNIVERSITY   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

DPP 4; DPP 4 inhibitors; Exenatide; GLP 1; GLP 1 analogues; GLP 1 mimetics; Liraglutide

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ALBUGON; BIGUANIDE DERIVATIVE; CJC 1131; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 3; EXENDIN 4; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HORMONE RECEPTOR STIMULATING AGENT; INCRETIN; INSULIN; ISOLEUCINE THIAZOLIDIDE; ISOPHANE INSULIN; LIRAGLUTIDE; LY 307161; METFORMIN; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN; SULFONYLUREA; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VALINE PYROLLIDIDE; VILDAGLIPTIN;

CLINICAL TRIAL; DRUG HALF LIFE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; SATIETY; SIDE EFFECT; STOMACH EMPTYING;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASES; GLUCAGON; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MOLECULAR MIMICRY; PROTEASE INHIBITORS; RATS; RECEPTORS, GLUCAGON;

ANIMALIA;

EID: 12244275009     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-826178     Document Type: Review

References (103)

1. Zimmet P. The burden of type 2 diabetes: are we doing enough? Diabetes Metab 2003; 29: 6S9-18
2. Ceriello A. The possible role of postprandial hyperglyceaemia in the pathogenesis of diabetic complications. Diabetologia 2003; 46: M9-M16
3. Turner RC The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998; suppl 3: C35-38
4. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-368
5. Consoli A. Role of liver in pathophysiology of NIDDM. Diabetes Care 1992; 15: 430-441
6. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19
7. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003; 32: 805-822
8. Ahrén B. Glucagon-like peptide 1 (GLP-1) - a gut hormone of potential interest in the treatment of diabetes. BioEssays 1998; 20: 642-651
9. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabet Metab Res Rev 2002; 18: 430-441
10. Ahrén B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diabet Rep 2003; 3: 365-372
11. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940
12. Drucker DJ. Glucagon-like peptides: rergulators of cell proliferation, differentiation and apoptosis. Mol Endocrinol 2003; 17: 161-171
13. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, di Mario U, Harlan DM, Perfetti R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 1344: 5149-5158
14. Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 1316-1322
15. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF. Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 1992; 15: 270-276
16. Nauck MA, Kleine N, Ørskov C, Holst JJ, Wilms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide-1 (7-36)amide in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744
17. Nauck MA, Sauerwaldf A, Ritzel R, Holst JJ, Schmiegel W. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea failure. Diabetes Care 1998; 21: 1925-1931
18. Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997; 40: 205-211
19. Nauck MA, Wollschlager D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36amide]) in patients with NIDDM. Diabetologia 1996; 39: 1546-1553
20. Juntti-Berggren L, Pigon J, Karpe F, Hamsten A, Gutniak M, Vignati L, Efendic S. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 1996; 19: 1200-1206
21. Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care 1997; 20: 1874- 1879
22. Ritzel R, Ørskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 1995; 38: 720-725
23. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830
24. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004; 36: 852-858
25. Deacon CF. Circulation and degradation of GlP and GLP-1. Horm Metab Res 2004; 36: 761-765
26. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24
27. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957
28. Rolin B, Deacon CF, Carr RD, Ahrén B. The major GLP-1 metabolite, GLP-1-(9-36) amide, does not affect glucose or insulin levels in mice. Eur J Pharmacol 2004; 494: 283-288
29. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenlus glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003; 88: 1772-1779
30. Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996; 318: 429-435
31. Hopsu-Havy VK, Glenner GG. A new dipeptide naphtylamidase hydrolyzing glycyl-prolyl-β-naphtylamide. Histochemie 1966; 7: 197-201
32. Lojda Z. Studies on dipeptidyl (amino) peptidase IV (glycyl-proline- naphtylamidase) II Blood vessels. Histochemistry 1979; 59: 153 -166
33. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, Markussen J. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995; 312 (Pt 3): 725-731
34. Bjerre Knudsen L. Glucagon-like peptide-1: The basis of a new class of treatment for type 2 diabetes. J Med Chem 2004; 47: 4128-4134
35. Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, Carr RD, Bjerre Knudsen L. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003; 140: 123-132
36. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001; 50: 2530-2539
37. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Bjerre Knudsen L. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E745-E752
38. Bock T, Pakkenberg B, Buschard K. The endocrine pancreas in nondiabetic rats after short-term and long-term treatment with the long-actingGLP-1 derivative NN2211. APMIS 2003; 111: 1117-1124
39. Klein T, Frandsen U, Heller RS, Serup P. IMPAN cells: a pancreatic model for differentiation into endocrine cells. Arch Biochem Biophys 2001; 395: 259-263
40. Ribel U, Larsen MO, Rolin B, Carr RD, Wilken M, Sturis J, Westergaard L, Deacon CF, Bjerre Knudsen L. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol 2002; 451: 217-225
41. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202
42. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25: 1398-1404
43. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Pørksen N, Schmitz O. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51: 424-429
44. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003; 52: 1786-1791
45. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194
46. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335-1342
47. Feinglos M, Saad MF, Pi-Sunyer FX, An B, Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 derivative, on glycaemic control and body weight in obese subjects with Type 2 diabetes. Diabetic Medicine 2004; in press
48. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002; 277: 35035-35043
49. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C, Drucker DJ. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003; 52: 751 -759
50. Lawrence B, Dreyfus J-F, Wen S, Guivarch P-H, Drucker DJ, Castaigne J-P. CJC-1131, a Long Acting GLP-1 Derivative, Exhibits an Extended Pharmacokinetic Profile in Healthy Human Volunteers. Diabetes 2003; 52 (Suppl. 1): A125
51. Benquet C, Léger R, Huang X, Thibaudeau K, Bridon D, Castaigne J-P. CJC-1131 (DAC: GLP-1) binds covalently in vivo to Endogenous Albumin: Update on the DAC Technology. Diabetes 2004; 53 (Suppl. 2): A116
52. Wen S, Chatenoud L, Lawrence B, Franco P, Castaigne J-P, Bach J-F. Lack of Immunogenicity of CJC-1131, a Long-Acting GLP-1 Analog for the Treatment of Type 2 diabetes. Diabetes 2004; 53 (Suppl. 2): A151
53. Bloom M, Bock J, Duttaroy A, Grzegorzewski K, Moore P, Ou Y, Wojcik S, Zhou X, Bell A. Albugon(TM) Fusion Protein: A long-acting analog of GLP-1 that provides lasting antidiabetic effect in animals. Diabetes 2003; 52 (Suppl. 1): A112
54. Kapitza C, Trautmann M, Heise T, Heinemann L, Patterson B. Daily administration of LY307161 SR (GLP-1 analog) normalizes blood glucose in type 2 diabetes. Diabetes 2002; 51 (Suppl. 2): A84
55. Raufman JP, Jensen RT, Sutliff VE, Pisano JJ, Gardner JD. Actions of Gila monster venom on dispersed acini from guinea pig pancreas. Am J Physiol 1982; 242: G470-G474
56. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-7405
57. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993; 42: 1678-1682
58. Rai A, Singh G, Raffaniello R, Eng J, Raufman JP. Actions of Helodermatidae venom peptides and mammalian glucagon-like peptides on gastric chief cells. Am J Physiol 1993; 265: G118-G125
59. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta cells. J Biol Chem 1993; 268: 19650-19655
60. Chen K, Petrella E, Young A. Effects of functional nephrectomy on clearance of exendin-4 in rats. Diabetes 1999; 48: A426
61. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, Young A. Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug Dev Res 2001; 53: 260-267
62. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999; 48: 1026-1034
63. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155-E161
64. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87: 1282-1290
65. Nielsen LL, Baron AD. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2003; 4: 401-405
66. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77-88
67. Young AA. Glucagon-like peptide-1, exendin and insulin sensitivity. In: Hansen B, Shafrir E (eds.). Insulin Resistance and Insulin Resistance Syndrome. New York: Harwood Academic, 2002: 235-262
68. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089
69. Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003; 284: E1072-E1079
70. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-2377
71. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53: 2397-2403
72. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 2002; 45: 1410-1415
73. 1c decline over 5 months in patients with type 2 diabetes failing oral agents in an open-label study. Diabetes 2003; Suppl. 3-LB
74. Kendall D, Riddle M, Rosenstock J, Zhuang D, Kim D, Fineman M, Baron A. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes mellitus treated with metformin and a sulfonylurea. Diabetes 2004; Suppl. 10-LB
75. Buckley DI, Lundquist P. Analysis of the degradation of insulinotropin [GLP-1 (7-37)] in human plasma and production of degradation resistant analogs. Regul Pept 1992; 40: 117
76. Deacon CF, Nauck MA, Toft-Nielsen L, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131
77. Kieffer TJ, McIntosh CHS, Pederson RA. Degradation of glucose-dependent insulinotropic peptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596
78. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47: 1663-1670
79. Deacon, CF, Wamberg S, Biev P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 2002; 172: 355-362
80. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in anesthetized pigs. Diabetes 1998; 47: 764-769
81. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucin thiazlodide. Diabetes 1998; 47: 1253-1258
82. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999; 42: 1324-1331
83. Ahrén B, Holst JJ, Mårtensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000; 404: 239-245
84. Kvist Reimer M, Holst JJ, Ahrén B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002; 146: 717-727
85. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CHS, Pederson RA. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002; 51: 943-950
86. Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 2002; 51: 1461-1469
87. Mitani H, Takimoto M, Kimura M. Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity. Jpn J Pharmacol 202; 88: 451-458
88. Pederson RA, Kieffer TJ, Pauly R, Kofod H, Kwong J, McIntosh CHS. The enteroinsular axis in dipeptidyl peptidase IV-negative rats. Metabolism 1996; 45: 1335-1341
89. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000; 97: 6874-6879
90. Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Yoshikawa S, Asano O, Tanaka I. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 2001; 284: 501-506
91. Yasuda N, Nagakura T, Yamazaki K, Inoue T, Tanaka I. Improvement of high fat-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life Sci 2002; 71: 227-238
92. Demuth HU, Hoffman T, Glund K, McIntosh CHS, Pederson RA, Fueker K, Fischer S, Hanefeld M. Single dose treatment of diabetic patients by the DP IV inhibitor P32/98. Diabetes 2000; 49 (Suppl 1): A102
93. Rothenburg P, Kalbag J, Smith H, Gingerich R, Nedelman J, Villhauer E, McLeod J, Hughes T. Treatment with a DPP-IV inhibitor, NVP-DPP728, increases prandial intact GLP-1 levels and reduces glucose exposure in humans. Diabetes 2000; 49 (Suppl 1): A39
94. Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Båvenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-875
95. Sörhede Winzell M, Ahrén B. The high-fat fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 2004; 53 (Suppl 3): S215-219
96. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084
97. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in met-formin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-2880
98. Herman GA, Zhao PL, Dietrich B, Golor G, Schrodter A, Keymuelen B, Lasseter KC, Kipnes MS, Milliard D, Tanen M, de Lepeleire I, Cilissen C, Stevens C, Tanaka W, Gottesdiener KM, Wagner JA. The DP-IV inhibitor MK-0431 enhances GLP-1 and recues glucose following an OGTT in type 2 diabetes. Diabetes 2004; 53: A82
99. Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE. Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha Roy R. The role of dopeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 2003; 278: 22418-22423
100. Ahrén B. Autonomic regulation of islet hormone secretion. Implications for health and disease. Diabetologia 2000; 43: 393-410
101. Hansotia T, Baggio LLK, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing glucoregulatory actionsof DPP-IV inhibitors. Diabetes 2004; 53: 1326-1335
102. Caldwyll CG, Chen P, He J, Parmee ER, Leiting B, Marsilio F, Patel RA, Wu JK, Eiermann GJ, Petrov A, He H, Lyons KA, Thornberry NA, Weber AE. Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2004; 14: 1265-1268
103. Lankas G, Leiting B, Roy RS, Eiermann G, Biftu T, Kim D, Ok H, Weber A, Thornberry NA. Inhibition of DPP8/9 results in toxicity in preclinical species: potential importance of selective dipeptidyl peptidase IV inhibition for the treatment of type 2 DM. Diabetes 2004; 53 (Suppl 2): A2